

Article

Subscriber access provided by DUESSELDORF LIBRARIES

Synthesis of Pyridyl-dihydrobenzooxaphosphole Ligands and Their Application in Asymmetric Hydrogenation of Unfunctionalized Alkenes

Bo Qu, Lalith P. Samankumara, Jolaine Savoie, Daniel R Fandrick, Nizar Haddad, Xudong Wei, Shengli Ma, Heewon Lee, Sonia Rodriguez, Carl A. Busacca, Nathan K. Yee, Jinhua J. Song, and Chris H. Senanayake

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/jo4024864 • Publication Date (Web): 10 Jan 2014 Downloaded from http://pubs.acs.org on January 14, 2014

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Synthesis of Pyridyl-dihydrobenzooxaphosphole Ligands and Their Application in Asymmetric Hydrogenation of Unfunctionalized Alkenes

Bo Qu,* Lalith P. Samankumara, Jolaine Savoie, Daniel R. Fandrick, Nizar Haddad, Xudong Wei, Shengli Ma,

Heewon Lee, Sonia Rodriguez, Carl A. Busacca, Nathan K. Yee, Jinhua J. Song, Chris H. Senanayake

Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA bo.qu@boehringer-ingelheim.com

Table of Contents Graphic





Synthesis of the electron rich 2-substituted-6-(phenylsulfonyl)pyridines is presented. A series of air-stable, tunable, *P*-chiral pyridyl-dihydrobenzooxaphosphole ligands were designed and synthesized by a diastereoselective S_NAr substitution of the corresponding sulfonyl pyridines. The ligands were successfully applied in the Ir-catalyzed asymmetric hydrogenation of unfunctionalized alkenes with good enantioselectivities.

Introduction

Chiral phosphine ligands have played a central role in the field of asymmetric catalysis toward the rapid synthesis of enantiomerically pure pharmaceuticals and fine chemicals.¹ Development of structurally novel, sterically or electronically tunable, and operationally convenient chiral phosphorus ligands continues to be of great interest in further broadening the scope of asymmetric hydrogenation as well as in the discovery of new efficient transition metal catalyzed asymmetric reactions.² Even though an impressive number of chiral phosphine ligands have been developed since the pioneering work of Kagan, Noyori, Knowles, and others,³ only a limited set of these has been applied in large scale chemical processes presumably due to their lengthy synthesis as well as the challenges associated with the fine tuning of the electronic and steric properties.⁴

Recently we have developed a rigid modular *P*-chiral dihydrobenzooxaphosphole core structure **1** (Scheme 1). A series of ligands such as BIBOP and POP were derived from this chiral intermediate to enable high enantioselectivities in the rhodium catalyzed asymmetric hydrogenation of functionalized alkenes, such as enamides and unsaturated aminoacid derivatives.⁵ BI-DIME has been demonstrated as a highly efficient ligand for the palladium catalyzed Suzuki-Miyuara and Buchwald-Hartwig couplings of sterically demanding substrates.⁶ Herein, we report the synthesis of a new series of air-stable chiral pyridyl-phosphine ligands (BoQPhos) and the application of these ligands in the iridium catalyzed asymmetric hydrogenation of *unfunctionalized* tri- and tetrasubstituted alkenes.

Scheme 1. Chiral ligands developed from the P-chiral dihydrobenzooxaphosphole 1



The Journal of Organic Chemistry

Despite the success of many chiral ligands applied for rhodium- and ruthenium-catalyzed hydrogenations particularly for alkenes bearing a coordinating group next to the C=C bond,⁷ unfunctionalized alkenes have remained a challenging class of substrates, as there are no functional groups in position to guide the catalyst in differentiating between the enantiofaces of the alkenes.⁸ Pfaltz and others have shown that P,N ligands such as phosphinooxazoline ligands (PHOX) are particularly effective for the Ir-catalyzed asymmetric hydrogenation of unfunctionalized alkenes and furnishing high enantioselectivities.⁹ Inspired by these results, we aimed to develop a new class of pyridyl-phosphine P,N ligands based on the dihydrobenzooxaphosphole core **1**. The notable features of these new P,N ligands are their tunability by variation of the substitution on both the phenyl and pyridyl rings. We anticipated that the steric and electronic variation of the substituents would have a great impact on the efficiency of their iridium complexes when applied to the asymmetric hydrogenation of unfunctionalized alkenes.

Results and Discussions

To construct the pyridyl-phosphines in a concise manner, S_NAr coupling of 2-sulfonylpyridines with the derivatives of 1 was explored due to the necessary acidity of the α -proton to the phosphorous atom in the dihydrobenzooxaphosphole core. The sulfonylpyridines are valuable building blocks, which can be easily displaced under nucleophilic substitution conditions to incorporate pyridine moieties into complex molecules.¹⁰ Unsubstituted sulfonylated pyridine **3a** was readily obtained from a direct S_NAr displacement of 2-chloropyridine with benzene sulfinic acid sodium salt in 80% yield in the presence of acetic acid (Scheme 2, Method **a**). However, no product formation was observed with 2-chloro-6phenylpyridine or electron rich 2-chloro-6-alkoxypyridines. Aryl sulfones are generally prepared by oxidation of the sulfides,¹¹ metal-catalyzed cross coupling of aryl halides with arenesulfinic acid salts,¹² or the corresponding electrophilic aromatic substitution reactions.¹³ Most of these methods are only applicable to the electron deficient aryl halides. Indeed, an alternative approach applying Cu(I) catalyzed coupling of 2-bromo-6-methoxypyridine with phenyl sulfinic acid salts provided a low yield for **3b** (< 20%). Gratifyingly, **3b** was obtained in 90% yield from S_NAr displacement of the 2,6-disulfonylated pyridine **2** (Method **b**). Even though not previously reported, pyridine disulfone **2** was readily synthesized

in 89% yield by treatment of the 2,6-dichloropyridine with phenyl sulfinic acid salt at 100 °C in DMAc.¹³ Similarly, 2-phenyl-6-(phenylsulfonyl)pyridine **3c** was obtained in 80% yield from the reaction with PhMgBr. 2-ethoxy-6-(phenylsulfonyl)pyridine **3d** and 2-phenoxy-6-(phenylsulfonyl)pyridine **3e** were also isolated in high yields, 91% and 88% respectively, by treatment with the corresponding alcohols in the presence of KHMDS. Electron rich 2-substituted 6-(phenylsulfonyl)pyridines could be readily prepared through Method **b**.

Scheme 2. Synthesis of phenylsulfonylpyridines



With sulfonylated pyridines in hand, S_NAr reaction of 2-(phenylsulfonyl)pyridine with chiral precursor **1a** was first evaluated. Subjecting the mixture to one equivalent of LDA at -78 °C provided only a 35% conversion. However, complete conversion was obtained by increasing the LDA stoichiometry to 3 equiv (Scheme 3). Two diastereomers were observed from the coupling. The *cis*-diastereomer was the initial major isomer right after MeOH quench at -78 °C. After warming up to rt, the *cis*-isomer gradually converted to the thermodynamically more stable *trans*-isomer with the bulky *tert*-butyl group positioned *trans* to the pyridyl functionality. High *trans:cis* ratio of >99:1 could be obtained after treating with additional aqueous NaOH. The trace amount of the *cis*-diastereomer was removed

easily by silica gel purification or by recrystallization. Pure **4a** was isolated in 85% yield. The absolute configuration of the *trans*-isomer was confirmed by the X-ray single crystal structure of phosphine oxide **4a**.¹⁴ Reduction of the P,N oxide **4a** with polymethylhydrosiloxane (PMHS) and $Ti(OiPr)_4$ conditions provided phosphine ligand **5a** as a white solid in 86% yield.





Figure 1. X-ray single crystal structure of 4a, ellipsoids at 50% probability

Under the same reaction conditions, a series of pyridyl-dihydrobenzooxaphosphole ligands **5b-f** were synthesized in good yields starting from **1** in two steps (Scheme 4). Both the S_NAr coupling and the reduction reactions are stereoselective. Phosphine oxides and free phosphines are all >99% ee.²⁰ The isolated free phosphines proved to be air-stable. Compound **5a** was exposed to air at ambient temperature for one month with no detectable amount of oxidation product as determined by ³¹P NMR analysis. The corresponding cationic iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BArF) complexes were then prepared according to known procedures and purified by silica gel chromatography.¹⁵ The iridium complexes of **6a-d** from the unsubstituted pyridyl phosphine ligands were obtained as red-orange solids. However, the iridium complexes **6e** and **6f** from the *ortho*-substituted pyridyl phosphine ligands were

obtained as light yellow solids. More importantly, the ¹H NMR spectroscopy of catalyst **6e** from the bismethoxy ligand **5e** showed only one methoxy signal at 3.96 ppm. The detailed NMR analyses indicated that complex **6e** is a five-membered chelate hydridoiridium derivative resulted by an intramolecular C-H activation of the methoxy group on pyridine.²¹ The cyclometalated methylene group was identified by two unequal ¹H signals at 6.72 and 7.32 ppm and one methylene group ¹³C NMR signal at 61.62 ppm from the DEPT ¹³C NMR spectroscopy. Additionally a metal hydride was located at -13.34 ppm as a doublet from coupling with the phosphorous atom. Similarly, hydridoiridium complex **6f** was formed by C-H bond oxidative addition of the phenyl substituent which is in close proximity to the metal center. The resulting hydridoiridium complexes **6e** and **6f** are stable in solution for at least one week (CDCl₃, 293 k).









The Journal of Organic Chemistry

Entry	Catalyst	Conv%	<i>er</i> of 8 a
1	6a	100%	86:14
2	6b	40%	72:28
3	6c	90%	88:12
4	6d	6%	77:23
5	6e	15%	52:48
6	6f	10%	55:45

With the new pyridyl-phosphorous iridium complexes in hand, asymmetric hydrogenation of tetrasubstituted 2,3-dimethylindene **7a** was examined using the complexes **6a-f** as catalysts (Table 1). Screening of solvents has identified methylene chloride as the best hydrogenation solvent. Complete conversion and good enantioselectivity of $86:14 \ er$ were obtained at 400 psi H₂ and 23 °C with Ir-complex **6a** derived from the unsubstituted pyridyl ligand **5a** (Table 1, entry 1). However the hydridoiridium complexes **6e** and **6f** impeded both the reactivity and the selectivity (entries 5 and 6). Aryl groups were also incorporated at the 4-position of the compound **1**; low reactivity and selectivity were observed with 4-phenyl substituted catalyst **6b** (entry 2) and 9-anthracenyl substituted **6d** (entry 4). To our delight, the catalyst **6c** obtained from incorporation of the 2,6-dimethoxyphenyl functionality produced **8a** with the optimal results of up to $88:12 \ er$ (entry 3).

Scheme 5. Asymmetric hydrogenation of alkenes with catalyst 6c



Catalyst **6c** was further evaluated on asymmetric hydrogenation of additional tri- and tetrasubstituted alkenes (Scheme 5). Treatment of *trans-* α -methylstilbene **7b** in the presence of complex **6c** produced the adduct **8b** in a 95:5 *er*. Reduction of phenyldihydronaphthalene **7c** with catalyst **6c** generated the adduct **8c** in an 88:12 *er*. Dihydronaphthalene **7d** is generally more difficult to hydrogenate enantioselectively; a good enantiomeric ratio of 90:10 was obtained for **8d** with an 80% conversion at 400 psi H₂ in the presence of catalyst **6c**. In comparison, the optimized PHOX ligand produced **8d** in an 89:11 *er* and 46% conversion.¹⁶ Recently we have reported a higher *er* of 95:5 for **8d** using the phosphine imidazoline based iridium BIPI 238 complex.¹⁷ Reduction of (*E*)-2-methyl-3-phenylpropenol (**7e**) containing an allylic hydroxyl group with catalyst **6c** provided the adduct **8e** in a 93:7 *er* and complete conversion.

Conclusions

A new method for the synthesis of electron rich 2-substituted 6-(phenylsulfonyl)pyridines was reported starting from 2,6-disulfonylated pyridine. A series of new air stable chiral pyridyldihydrobenzooxaphosphole ligands (BoQPhos) were conveniently synthesized by diastereoselective S_NAr displacement of the key intermediate **1** with the sulfonylated pyridine derivatives. Initial application of these ligands to the asymmetric hydrogenation of challenging unfunctionalized alkenes yielded good enantioselectivities. The electronic and steric properties of the ligand system can be readily tuned by the judicious choice of substitutions on the chiral core structure and on the pyridine ring thereby providing a

facile approach to the ligand optimization toward a diverse number of transition metal catalyzed asymmetric transformations.

Experimental Section

General Methods. All starting materials and reagents were purchased from the commercial sources and used without further purification. All ¹H and ¹³C NMR data were referenced to the internal deuterated solvent relative to TMS at 0 ppm. High resolution mass spectroscopy was performed on a TOF instrument with ESI and positive and negative ionization modes. Flash chromatography was performed on an automated system with silica columns. Compounds 1a, ^{5a} 1b, ^{5a} 1c, ^{6a} and $1d^{18}$ have been previously described. Sulfonyl pyridines $3a^{11}$ and $3c^{19}$ are known compounds, alternative syntheses are described herein.

Synthesis of the sulfonyl pyridines

2,6-Bis(phenylsulfonyl)pyridine (2). To a N₂ purged reactor was charged 10.0 g (67.57 mmol) of 2,6dichloropyridine, 16.64 g (101.4 mmol) of sodium benzenesulfinate, 5.6 g (20.73 mmol) of tetrabutylammonium chloride and 100 mL of N,N-dimethylacetamide. The mixture was heated to 100 °C and stir for 4 h. Then another portion of 16.64 g (101.4 mmol) sodium benzenesulfinate was charged and stir at 100 °C for 14 h until more than 95% conversion was obtained. The mixture was cooled down to rt and 300 mL of water was added to observe formation of white precipitates. The slurry was stirred at rt for 1 h. The solid was filtered and washed with 20 ml of isopropanol. 21.6 g of **2** was obtained as a white solid after drying under vacuum at 50 °C, 89% yield; mp 178.1-180.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, *J* = 7.6 Hz, 2H), 8.18-8.16 (m, 1H), 7.94-7.91 (m, 4H), 7.66 (tt, *J* = 7.5, 1.2 Hz, 2H), 7.51 (t, *J* = 7.8 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 140.6, 137.4, 134.2, 129.4, 129.1, 124.2; HRMS (ESI) *m/z* 360.0358 (M + H⁺), calc. for C₁₇H₁₄NO₄S₂ 360.0359.

2-(Phenylsulfonyl)pyridine (3a). A 500 mL reactor was charged 113.6 g (1.0 mol) 2-chloropyridine, first portion of PhSO₂Na (82 g, 0.5 mol, 0.5 equiv), 226 ml acetic acid and 72 mL water. The mixture was heated to 90 °C and stirred for 2 h. Then 0.75 equiv of PhSO₂Na was added in three portions (41 g, 0.25

equiv each) in 15 h. HPLC analysis showed >97% conversion. The mixture was cooled down to rt and 150 mL water was added. Stirring was continued for 30 min. The slurry was filtered and the crude solid was recharged to a reactor and 250 mL of isopropanol was added. The slurry was stirred at 60 °C for 30 min and then cooled down to rt. The resulted white solid was filtered and dried in the oven to give 175 g of **3a** in 80% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 4.8 Hz, 1H), 8.21 (d, *J* = 7.9 Hz, 1H), 8.08 (m, 2H), 7.95 (dt, *J* = 7.8, 1.7 Hz, 1H), 7.60 (m, 1H), 7.55 (m, 2H), 7.48 (ddd, *J* = 7.6, 4.7, 1.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 150.5, 138.9, 138.1, 133.8, 129.1, 128.9, 126.9, 122.2.

2-Methoxy-6-(phenylsulfonyl)pyridine (3b). To a N₂ purged reactor was charged 5.0 g (13.9 mmol) of **2a** and 50 mL of anhydrous THF to result a slurry. MeONa (25 wt% in MeOH) (1.1 equiv) was added drop wise to the stirring reaction mixture. The resulting slurry was stirred for 1 h at room temperature. A complete conversion was observed by LC-MS. The slurry was filtered and washed with IPA; dried in oven overnight at 50 °C to give 1.94 g **3b** as a white solid. The mother liquor was concentrated and 15 mL of IPA was added and warmed until complete dissolution. The mixture was cooled down to 10 °C and held for 1 h. The second crop of solid was filtered and dried to yield another 1.17 g of white solid, total 90% yield; mp 74.6-75.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.12-8.09 (m, 2H), 7.78-7.73 (m, 2H), 7.64 (tt, *J* = 7.4, 1.3 Hz, 1H), 7.58-7.53 (m, 2H), 6.88 (dd, *J* = 7.7, 1.4 Hz, 1H), 3.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.0, 155.7, 139.7, 138.9, 133.6, 129.1, 128.9, 115.5, 114.9, 54.0; HRMS (ESI) *m/z* 250.0528 (M + H⁺), calc. for C₁₂H₁₂NO₃S 250.0532.

2-Phenyl-6-(phenylsulfonyl)pyridine (3c). To a stirring solution of *bis*-(phenylsulfonyl)pyridine **2a** (1.0 g, 2.78 mmol) in 10 mL THF at room temperature was charged 1.0 M PhMgBr (5.56 ml, 2.0 equiv) slowly over a period of 10 min. The progress of the reaction was monitored by LC-MS. Upon complete consumption of the starting material after 2 h, the mixture was quenched with MeOH (2 mL). The crude mixture was then evaporated to dryness and **3c** was isolated by flash column chromatography (silica gel, 15% ethyl acetate in hexanes) to yield 656 mg white solid after dryness, 80% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.14-8.08 (m, 3H), 7.95-7.91 (m, 3H), 7.83-7.86 (m, 1H), 7.62-7.51 (m, 3H), 7.46-7.40 (m, 3H);

¹³C NMR (100 MHz, CDCl₃) δ 158.7, 158.0, 138.9, 138.7, 137.1, 133.7, 130.0, 129.2, 128.9, 128.8, 127.0, 123.1, 119.8.

2-Ethoxy-6-(phenylsulfonyl)pyridine (3d). To a N₂ purged reactor was charged 1.08 g (3.0 mmol) of 2,6-bis(phenylsulfonyl)pyridine **2**, 7 mL of anhydrous THF and 0.18 mL of EtOH (3.06 mmol, 1.02 equiv). 3.0 mL of 1.0 M KHMDS in THF (3.0 mmol, 1.0 equiv) was added drop wise to the stirring reaction at rt. The resulting mixture was stirred for 1 h at rt. A complete conversion was observed by LC-MS. Upon completion, 5 mL water was added. The mixture was then concentrated and 10 mL EtOAc was added. The layers were separated and the aqueous layer was further extracted. The combined organic layer was dried and purified on silica to yield 723 mg of **3d** as a white solid after dryness, 91% yield; mp 95.1-96.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 7.6 Hz, 2H), 7.74 (m, 2H), 7.61 (t, *J* = 7.5 Hz, 1H), 7.55 (t, *J* = 7.7 Hz, 2H), 6.84 (dd, *J* = 7.3, 1.7 Hz, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 1.28 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.7, 155.6, 139.7, 139.0, 133.5, 129.0, 128.8, 115.6, 114.6, 62.6, 14.1; HRMS (ESI) *m/z* 264.0684 (M + H⁺), calc. for C₁₃H₁₄NO₃S 264.0694.

2-Phenoxy-6-(phenylsulfonyl)pyridine (3e). Same procedures as above with 288 mg of phenol (3.06 mmol, 1.02 equiv). 820 mg of **3e** was isolated as a white solid, 88% yield; mp 108.1-109.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.88-7.83 (m, 4H), 7.58 (t, *J* = 7.5 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 2H), 7.36 (t, *J* = 7.9 Hz, 2H), 7.26 (m, 1H), 7.05 (m, 1H), 6.99 (d, *J* = 8.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 156.3, 152.9, 140.8, 138.3, 133.5, 129.5, 129.3, 128.7, 125.2, 121.5, 115.7, 115.3; HRMS (ESI) *m/z* (M + H⁺) 312.0678, calc. for C₁₇H₁₄NO₃S 312.0689.

Synthesis of the phosphine oxides

(2R,3S)-3-(tert-butyl)-4-methoxy-2-(pyridin-2-yl)-2H-benzo[d][1,3]oxaphosphole 3-oxide (4a).

Intermediate **1a** (1.0 g, 4.163 mmol) and pyridine sulfone **3a** (0.913 g, 4.163 mmol) were dissolved in 10 ml of anhydrous THF under argon. The mixture was cooled to -78 °C with a dry ice/acetone bath. To the stirred solution 2.64 mL (12.5 mmol) of LDA (2.0 M in THF/ethylbenzene) was added drop wise. The internal temperature was maintained under -70 °C for an additional hour. Upon completion, the reaction was quenched with MeOH at -78 °C. The mixture was warmed to rt and stirring continued for 2 h. The

reaction mixture should be basic at PH \ge 12. Aqueous NaOH (30 wt%) was added if necessary. The mixture was then concentrated to dryness. The organic layer was extracted with CH₂Cl₂ and dried with anhydrous Na₂SO₄ and compound **4a** was purified on silica with 5% MeOH in CH₂Cl₂ to yield 1.2 g of white solid after dryness, 91% yield; mp 186.1-188.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.7 Hz, 1H), 7.68 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.45 (t, *J* = 8.3 Hz, 1H), 7.40 (dd, *J* = 8.0, 0.5 Hz, 1H), 7.21 (t, *J* = 6.2 Hz, 1H), 6.68 (dd, *J* = 8.3, 3.0 Hz, 1H), 6.53 (dd, *J* = 8.3, 4.2 Hz, 1H), 5.67 (d, *J*_{H-P} = 2.9 Hz, 1H), 3.88 (s, 3H), 1.39 (d, *J*_{H-P} = 16.6 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6 (d, *J*_{C-P} = 15.0 Hz), 161.5 (d, *J*_{C-P} = 1.9 Hz), 154.4 (d, *J*_{C-P} = 3.4 Hz), 149.2, 136.7, 136.6, 123.0 (d, *J*_{C-P} = 1.8 Hz), 122.3 (d, *J*_{C-P} = 2.2 Hz), 106.1 (d, *J*_{C-P} = 5.1 Hz), 103.6 (d, *J*_{C-P} = 5.5 Hz), 103.2 (d, *J*_{C-P} = 89.2 Hz), 79.1 (d, *J*_{C-P} = 53.9 Hz), 55.6, 34.3 (d, *J*_{C-P} = 73.9 Hz), 25.0; ³¹P NMR (160 MHz, CDCl₃) δ 61.65; HRMS (ESI) *m/z* 318.1237 (M + H⁺), calc. for C₁₇H₂₁NO₃P 318.1254.

(2*R*,3*S*)-3-(*tert*-butyl)-4-phenyl-2-(pyridin-2-yl)-2H-benzo[*d*][1,3]oxaphosphole 3-oxide (4b). 1.09 g of white solid was isolated after purification with 0-2% MeOH in CH₂Cl₂, 72% yield; mp 99.2-101.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 5.0 Hz, 1H), 7.76-7.73 (m, 3H), 7.57 (dt, *J* = 7.9, 0.9 Hz, 1H), 7.48 (dd, *J* = 8.0, 0.9 Hz, 1H), 7.18-7.34 (m, 3H), 7.26-7.22 (m, 1H), 7.13-7.07 (m, 2H), 5.71 (d, *J* = 1.0 Hz, 1H), 0.91 (d, *J*_{H-P} = 16.5 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 164.6 (d, *J*_{C-P} = 17.6 Hz), 154.8 (d, *J*_{C-P} = 3.7 Hz), 149.3 (d, *J*_{C-P} = 1.2 Hz), 147.0 (d, *J*_{C-P} = 5.6 Hz), 140.6 (d, *J*_{C-P} = 1.8 Hz), 136.7 (d, *J*_{C-P} = 1.8 Hz), 134.9 (d, *J*_{C-P} = 1.9 Hz), 129.9, 128.5, 128.4, 123.9 (d, *J*_{C-P} = 7.8 Hz), 122.9 (d, *J*_{C-P} = 1.8 Hz), 121.6 (d, *J*_{C-P} = 2.2 Hz), 112.8 (d, *J*_{C-P} = 85.9 Hz), 112.4 (d, *J*_{C-P} = 5.3 Hz), 77.8 (d, *J*_{C-P} = 55.6 Hz), 34.6 (d, *J*_{C-P} = 71.3 Hz), 24.4; ³¹P NMR (160 MHz, CDCl₃) δ 62.19; HRMS (ESI) *m/z* 364.1459 (M + H⁺), calc. for C₂₂H₂₃NO₂P 364.1461.

(2*R*,3*S*)-3-(*tert*-butyl)-4-(2,6-dimethoxyphenyl)-2-(pyridin-2-yl)-2H-benzo[*d*][1,3]oxaphosphole 3-oxide (4c). 1.37 g white solid was obtained after purification with 100% EtOAc, 78% yield; mp 186.0-188.4 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, *J* = 4.7 Hz, 1H), 7.68 (dt, *J* = 7.8, 1.6 Hz, 1H), 7.56 (t, *J* = 7.8 Hz, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.27 (t, *J* = 8.3 Hz, 1H), 7.21 (t, *J* = 6.2 Hz, 1H), 7.05 (dd, *J* = 8.2, 3.2 Hz, 1H), 6.98 (dd, *J* = 7.4, 3.2 Hz, 1H), 6.58 (dd, *J* = 8.2, 5.0 Hz, 2H), 5.60 (d, *J* = 1.6 Hz, 1H), 3.74

 (s, 3H), 3.58 (s, 3H), 0.95 (d, $J_{\text{H-P}} = 16.2 \text{ Hz}$, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 164.2 (d, $J_{\text{C-P}} = 17.7$ Hz), 158.8, 157.3, 154.9 (d, $J_{\text{C-P}} = 3.1 \text{ Hz}$), 149.1 (d, $J_{\text{C-P}} = 0.9 \text{ Hz}$), 138.8 (d, $J_{\text{C-P}} = 5.3 \text{ Hz}$), 136.4, 134.3, 129.9, 125.6 (d, $J_{\text{C-P}} = 8.4 \text{ Hz}$), 122.9 (d, $J_{\text{C-P}} = 1.4 \text{ Hz}$), 122.4 (d, $J_{\text{C-P}} = 2.3 \text{ Hz}$), 117.4 (d, $J_{\text{C-P}} = 2.0 \text{ Hz}$), 114.7 (d, $J_{\text{C-P}} = 89.5 \text{ Hz}$), 112.3 (d, $J_{\text{C-P}} = 5.4 \text{ Hz}$), 104.6, 103.0, 78.2 (d, $J_{\text{C-P}} = 55.3 \text{ Hz}$), 56.1, 55.4, 34.2 (d, $J_{\text{C-P}} = 71.8 \text{ Hz}$), 23.9 (d, $J_{\text{C-P}} = 0.7 \text{ Hz}$); ³¹P NMR (200 MHz, CDCl₃) δ 60.11; HRMS (ESI) *m/z* 424.1654 (M + H⁺), calc. for C₂₄H₂₇NO₄P 424.1672.

(2R,3S)-4-(anthracen-9-yl)-3-(tert-butyl)-2-(pyridin-2-yl)-2H-benzo[d][1,3]oxaphosphole 3-oxide

(4d). 1.73 g white solid was obtained after purification with 0-2% MeOH in CH₂Cl₂, 90% yield; mp 243-246 °C (decomp). ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 5.0 Hz, 1H), 8.51 (s, 1H), 8.05 (d, *J* = 8.4 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 1H), 7.76-7.69 (m, 3H), 7.62 (t, *J* = 8.6 Hz, 2H), 7.47-7.36 (m, 4H), 7.30 (dd, *J* = 8.4, 2.6 Hz, 1H), 7.22 (d, *J* = 6.0 Hz, 1H), 7.16 (dd, *J* = 7.2, 3.2 Hz, 1H), 5.60 (d, *J* = 4.4 Hz, 1H), 0.45 (d, *J*_{H-P} = 16.5 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 164.9 (d, *J*_{C-P} = 16.2 Hz), 154.3 (d, *J*_{C-P} = 3.2 Hz), 148.9, 142.1 (d, *J*_{C-P} = 5.6 Hz), 136.6 (d, *J*_{C-P} = 1.4 Hz), 134.5 (d, *J*_{C-P} = 1.5 Hz), 134.4 (d, *J*_{C-P} = 1.9 Hz), 131.3, 131.1, 130.3 (d, *J*_{C-P} = 4.5 Hz), 128.7, 128.4, 127.8. 127.2, 126.5 (d, *J*_{C-P} = 8.1 Hz), 126.2, 125.9, 125.7, 125.4, 124.8, 123.3 (d, *J*_{C-P} = 5.7 Hz), 33.8 (d, *J*_{C-P} = 71.3 Hz), 24.0; ³¹P NMR (160 MHz, CDCl₃) δ 58.55; HRMS (ESI) *m/z* 464.1770 (M + H⁺), calc. for C₃₀H₂₇NO₂P 464.1774.

(2*R*,3*S*)-3-(*tert*-butyl)-4-methoxy-2-(6-methoxypyridin-2-yl)-2H-benzo[*d*][1,3]oxaphosphole 3-oxide (4e). 1.18 g white solid was obtained after purification with 80% EtOAc in hexanes, 82% yield; mp 164.9-167.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (t, *J* = 7.7 Hz, 1H), 7.44 (t, *J* = 8.2 Hz, 1H), 6.98 (d, *J* = 7.4 Hz, 1H), 6.69 (dd, *J* = 8.4, 2.6 Hz, 1H), 6.64 (d, *J* = 8.4 Hz, 1H), 6.51 (dd, *J* = 8.0, 4.0 Hz, 1H), 5.55 (d, *J* = 1.8 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 1.41 (d, *J*_{H-P} = 16.6 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6 (d, *J*_{C-P} = 15.1 Hz), 163.4 (d, *J*_{C-P} = 1.6 Hz), 161.6 (d, *J*_{C-P} = 1.9 Hz), 151.8 (d, *J*_{C-P} = 4.3 Hz), 139.1 (d, *J*_{C-P} = 5.6 Hz), 102.4 (d, *J*_{C-P} = 89.2 Hz), 78.6 (d, *J*_{C-P} = 53.9 Hz), 55.6, 53.4, 34.3 (d, *J*_{C-P} = 74.3 Hz), 25.1; ³¹P NMR (160 MHz, CDCl₃) δ 61.51; HRMS (ESI) *m/z* 348.1350 (M + H⁺), calc. for C₁₈H₂₃NO₄P 348.1359.

(2*R*,3*S*)-3-(*tert*-butyl)-4-methoxy-2-(6-phenylpyridin-2-yl)-2H-benzo[*d*][1,3]oxaphosphole 3-oxide (4f). 1.16 g white solid was obtained after purification with 50% EtOAc in hexanes, 71% yield; mp 172.2-174.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 7.9 Hz, 2H), 7.75 (t, *J* = 7.8 Hz, 1H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.48-7.35 (m, 5H), 6.71 (dd, *J* = 8.2, 2.9 Hz, 1H), 6.54 (dd, *J* = 8.1, 4.1 Hz, 1H) 5.77 (d, *J* = 3.3 Hz, 1H), 3.88 (s, 3H), 1.45 (d, *J* = 16.5 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7 (d, *J*_{C-P} = 15.0 Hz), 161.5 (d, *J*_{C-P} = 1.9 Hz), 156.6 (d, *J*_{C-P} = 1.2 Hz), 154.2 (d, *J*_{C-P} = 3.6 Hz), 139.2, 137.5 (d, *J*_{C-P} = 1.7 Hz), 136.6, 128.9, 128.6, 127.0, 120.6 (d, *J*_{C-P} = 2.4 Hz), 119.7 (d, *J*_{C-P} = 1.9 Hz), 106.2 (d, *J*_{C-P} = 73.8 Hz), 103.5 (d, *J*_{C-P} = 5.6 Hz), 102.7 (d, *J*_{C-P} = 89.0 Hz), 79.5 (d, *J*_{C-P} = 53.2 Hz), 55.6, 34.3 (d, *J*_{C-P} = 73.8 Hz), 25.2; ³¹P NMR (160 MHz, CDCl₃) δ 61.24; HRMS (ESI) *m/z* 394.1572 (M + H⁺), calc. for C₂₃H₂₅NO₃P 394.1567.

General procedure for the reduction of phosphine oxides

2-((2*R***,3***R***)-3-(***tert***-butyl)-4-methoxy-2,3-dihydrobenzo[***d***][1,3]oxaphosphol-2-yl)pyridine (5a). To a Schlenk flask under argon was added 4a** (500 mg, 1.576 mmol), THF (10 mL), PMHS (1.2 mL) and Ti(O*i*Pr)₄ (0.93 mL, 3.15 mmol). The mixture was stirred at 65 °C for 14 h. Upon complete conversion by ³¹P NMR analysis, the mixture was concentrated under vacuum. Then the flask was cooled to 0 °C and 20 ml of degassed 30% aqueous NaOH was added slowly with caution. Extreme H₂ gas evolution was observed in the beginning. After complete addition the mixture was heated to 65 °C and stirred for 1 h. The mixture was cooled down to rt and the product was extracted with degassed MTBE (3 x 30 mL) under argon. The combined organic layer was filtered through a plug of neutral alumina with anhydrous MgSO₄ on the top. 410 mg of **5a** was obtained as a white solid after dryness, 86% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 4.7 Hz, 1H), 7.51 (td, *J* = 7.7, 1.6 Hz, 1H), 7.28 (t, *J* = 8.1 Hz, 1H), 7.10 (d, *J* = 7.8 Hz, 1H), 7.06 (t, *J* = 6.2 Hz, 1H), 6.72 (d, *J* = 8.2 Hz, 1H), 6.47 (dd, *J* = 8.1, 3.6 Hz, 1H), 6.02 (s, 1H), 3.78 (s, 3H), 1.11 (d, *J*_{H-P} = 12.4 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6 (d, *J*_{C-P} = 15.2 Hz), 161.5 (d, *J*_{C-P} = 1.8 Hz), 154.4 (d, *J*_{C-P} = 3.6 Hz), 149.2 (d, *J*_{C-P} = 0.8 Hz), 136.7, 136.6, 123.0 (d, *J*_{C-P} =

1.7 Hz), 122.2 (d, $J_{C-P} = 2.4$ Hz), 106.1 (d, $J_{C-P} = 5.2$ Hz), 103.6 (d, $J_{C-P} = 5.6$ Hz), 103.2 (d, $J_{C-P} = 89.2$ Hz), 79.1 (d, $J_{C-P} = 53.8$ Hz), 55.6, 34.2 (d, $J_{C-P} = 73.7$ Hz), 25.0; ³¹P NMR (160 MHz, CDCl₃) δ 12.85; HRMS (ESI) *m/z* 302.1319 (M + H⁺), calc. for C₁₇H₂₁NO₂P 302.1304.

2-((2*R***,3***R***)-3-(***tert***-butyl)-4-phenyl-2,3-dihydrobenzo[***d***][1,3]oxaphosphol-2-yl)pyridine (5b). 383 mg white solid, 70% yield. ¹H NMR (500 MHz, CDCl₃) \delta 8.63 (d,** *J* **= 4.5 Hz, 1H), 7.59-7.62 (m, 3H), 7.42 (t,** *J* **= 7.8 Hz, 1H), 7.25-7.35 (m, 4H), 7.14 (t,** *J* **= 6.7 Hz, 1H), 7.08 (d,** *J* **= 8.0 Hz, 1H), 7.05 (dd,** *J* **= 7.4 Hz, 3.4 Hz, 1H), 6.03 (s, 1H), 0.79 (d,** *J* **= 12.2 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) \delta 164.4, 161.3 (d,** *J***_{C-P} = 14.3 Hz), 149.6 (d,** *J***_{C-P} = 1.7 Hz), 146.5 (d,** *J***_{C-P} = 12.9 Hz), 142.1, 136.7 (d,** *J***_{C-P} = 1.2 Hz), 131.6, 129.3, 129.1, 128.4, 127.4, 122.6 (d,** *J***_{C-P} = 2.8 Hz), 121.9 (d,** *J***_{C-P} = 2.5 Hz), 120.6 (d,** *J***_{C-P} = 22.3 Hz), 119.2 (d,** *J***_{C-P} = 3.5 Hz), 109.9, 85.3 (d,** *J***_{C-P} = 27.4 Hz), 32.8 (d,** *J***_{C-P} = 22.6 Hz), 26.8 (d,** *J***_{C-P} = 13.8 Hz); ³¹P NMR (200 MHz, CDCl₃) \delta 15.38; HRMS (ESI)** *m/z* **348.1512 (M + H⁺), calc. for C₂₂H₂₃NOP 348.1512.**

2-((2R,3R)-3-(tert-butyl)-4-(2,6-dimethoxyphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphol-2-

yl)pyridine (5c). 407 mg white solid, 75% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 4.7 Hz, 1H), 7.58 (dt, J = 8.0, 1.5 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.26-7.21 (m, 2H), 7.12 (t, J = 6.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.93 (dd, J = 7.6, 3.2 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 5.99 (s, 1H), 3.73 (s, 3H), 3.26 (s, 3H), 0.88 (d, $J_{\text{H-P}}$ = 12.2 Hz, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 161.7 (d, $J_{\text{C-P}}$ = 14.2 Hz), 157.6, 156.9, 149.2 (d, $J_{\text{C-P}}$ = 1.5 Hz), 139.1 (d, $J_{\text{C-P}}$ = 17.0 Hz), 136.5, 130.9, 129.1, 124.4 (d, $J_{\text{C-P}}$ = 4.1 Hz), 123.9 (d, $J_{\text{C-P}}$ = 17.1 Hz), 121.6 (d, $J_{\text{C-P}}$ = 2.4 Hz), 119.5 (d, $J_{\text{C-P}}$ = 3.7 Hz), 119.3 (d, $J_{\text{C-P}}$ = 21.5 Hz), 109.3, 104.4, 103.5, 86.0 (d, $J_{\text{C-P}}$ = 28.1 Hz), 55.43, 55.41, 31.9 (d, $J_{\text{C-P}}$ = 21.1 Hz), 26.7 (d, $J_{\text{C-P}}$ = 14.7 Hz); ³¹P NMR (160 MHz, CDCl₃) δ 17.71; HRMS (ESI) *m/z* 408.1700 (M + H⁺), calc. for C₂₄H₂₇NO₃P 408.1723.

2-((2*R*,3*R*)-4-(anthracen-9-yl)-3-(*tert*-butyl)-2,3-dihydrobenzo[*d*][1,3]oxaphosphol-2-yl)pyridine (5d). 613 mg white solid, 87% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.4-8.2 (m, 2H), 7.80-7.76 (m, 3H), 7.48-6.79 (m, 11H), 5.88 (s, 1H), 0.45 (d, *J*_{H-P} = 11.5 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 164.6, 161.2 (d, *J*_{C-P} = 14.5 Hz), 149.7, 142.8 (d, *J*_{C-P} = 16.6 Hz), 136.6, 136.0, 131.5, 131.3, 130.6, 128.9, 128.6, 128.3,

127.2, 127.0, 126.9, 125.8 (d, $J_{C-P} = 3.6 \text{ Hz}$), 125.6, 125.4, 125.3, 124.9, 124.8 (d, $J_{C-P} = 21.3 \text{ Hz}$), 121.9 (d, $J_{C-P} = 2.0 \text{ Hz}$), 119.3 (d, $J_{C-P} = 3.8 \text{ Hz}$), 110.4, 86.2 (d, $J_{C-P} = 27.6 \text{ Hz}$), 31.6 (d, $J_{C-P} = 22.4 \text{ Hz}$), 27.1 (d, $J_{C-P} = 14.6 \text{ Hz}$); ³¹P NMR (200 MHz, CDCl₃) δ 15.46; HRMS (ESI) *m/z* 448.1823 (M + H⁺), calc. for C₃₀H₂₇NOP 448.1825.

2-((2R,3R)-3-(tert-butyl)-4-methoxy-2,3-dihydrobenzo[d][1,3]oxaphosphol-2-yl)-6-methoxypyridine

(5e). Same procedure as above with addition of 2.1 mL of PMHS, 465 mg white solid was obtained in 89% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.41 (t, $J_{\text{H-P}} = 7.8$ Hz, 1H), 7.29 (t, $J_{\text{H-P}} = 8.2$ Hz, 1H), 6.74 (d, $J_{\text{H-P}} = 7.5$ Hz, 1H), 6.70 (d, $J_{\text{H-P}} = 8.2$ Hz, 1H), 6.52 (d, $J_{\text{H-P}} = 8.2$ Hz, 1H), 6.48 (dd, $J_{\text{H-P}} = 8.2$, 3.7 Hz, 1H), 5.92 (s, 1H), 3.88 (s, 3H), 3.79 (s, 3H), 1.13 (d, $J_{\text{H-P}} = 12.4$ Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 165.4, 163.5 (d, $J_{\text{C-P}} = 1.9$ Hz), 162.2 (d, $J_{\text{C-P}} = 11.8$ Hz), 158.7 (d, $J_{\text{C-P}} = 14.6$ Hz), 138.9 (d, $J_{\text{C-P}} = 1.2$ Hz), 132.3, 111.1 (d, $J_{\text{C-P}} = 3.8$ Hz), 109.6 (d, $J_{\text{C-P}} = 17.5$ Hz), 108.7 (d, $J_{\text{C-P}} = 2.6$ Hz), 104.2, 103.1 (d, $J_{\text{C-P}} = 1.9$ Hz), 85.8 (d, $J_{\text{C-P}} = 27.0$ Hz), 55.4, 53.1, 33.3 (d, $J_{\text{C-P}} = 22.4$ Hz), 27.2 (d, $J_{\text{C-P}} = 14.3$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 14.24; HRMS (ESI) *m/z* (M + H⁺) 332.1401, calc. for C₁₈H₂₃NO₃P 332.1410.

2-((2R,3R)-3-(tert-butyl)-4-methoxy-2,3-dihydrobenzo[d][1,3]oxaphosphol-2-yl)-6-phenylpyridine

(5f). 386 mg white solid, 65% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.02-8.04 (m, 2H), 7.60 (t, *J* = 7.8 Hz, 1H), 7.55-7.52 (m, 1H), 7.46-7.43 (m, 2H), 7.40-7.37 (m, 1H), 7.31 (t, *J* = 8.1 Hz, 1H), 7.09 (d, *J* = 7.7 Hz, 1H), 6.76 (d, *J* = 8.1 Hz, 1H), 6.50 (dd, *J* = 8.2, 3.6 Hz, 1H), 6.14 (s, 1H), 3.80 (s, 3H), 1.17 (d, *J* = 12.4 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 165.4, 162.2 (d, *J*_{C-P} = 11.7 Hz), 161.2 (d, *J*_{C-P} = 14.8 Hz), 156.5 (d, *J*_{C-P} = 1.9 Hz), 139.2, 137.3 (d, *J*_{C-P} = 1.2 Hz), 132.4, 128.9, 128.6, 126.9, 118.2 (d, *J*_{C-P} = 2.6 Hz), 117.2 (d, *J*_{C-P} = 3.5 Hz), 109.6 (d, *J*_{C-P} = 17.7 Hz), 104.2, 103.2 (d, *J*_{C-P} = 2.0 Hz), 86.3 (d, *J*_{C-P} = 27.3 Hz), 55.4, 32.5 (d, *J*_{C-P} = 22.4 Hz), 27.3 (d, *J*_{C-P} = 14.2 Hz); ³¹P NMR (200 MHz, CDCl₃) δ 14.52; HRMS (ESI) *m/z* (M + H⁺) 378.1600, calc. for C₂₃H₂₅NO₂P 378.1617.

General procedure for the synthesis of iridium complexes

{2-((2*R*,3*R*)-3-(*tert*-butyl)-4-methoxy-2,3-dihydrobenzo[*d*][1,3]oxaphosphol-2-yl)pyridine}(η^4 -1,5cyclooctadiene)iridium (I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (6a). A solution of 5a (100 mg, 0.332 mmol) and [IrCl(COD)]₂ (115.0 mg, 0.166 mmol) in degassed CH₂Cl₂ (6 mL) was heated for 1 h at 45 °C under argon. After cooling to rt, NaBAr_F (318 mg, 0.348 mmol) was added followed immediately by 10 ml of degassed water. The two layers were stirred vigorously for 30 min. After separation of the layers, the aqueous layer was extracted twice with CH_2Cl_2 (2 mL). The combined organic layer was dried over Na_2SO_4 and concentrated to 1 mL. The mixture was then passed through a short plug of silica under argon using CH_2Cl_2 as eluent. The center of the first orange fraction was collected and dried to give 413 mg of **6a** as a red-orange solid, 85% yield. ¹H NMR (500 MHz, CD₂Cl₂) δ 8.09 (d, J = 6.0 Hz, 1H), 8.05 (t, J = 7.6 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.63 (s, BArF), 7.47 (s, BArF), 7.42 (t, J = 6.8 Hz, 1H), 7.32 (t, J = 8.3 Hz, 1H), 6.52-6.55 (m, 2H), 5.96 (s, 1H), 5.25-5.28 (m, 1H), 5.05 (m, 1H), 4.83-4.88 (m, 1H), 4.41-4.43 (m, 1H), 3.84 (s, 3H), 2.61-2.65 (m, 1H), 2.30-2.42 (m, 2H), 2.22-2.28 (m, 2H), 2.01-2.07 (m, 1H), 1.72-1.86 (m, 2H), 1.15 (d, $J_{H-P} = 16.2$ Hz, 9H); ¹³C NMR (125 MHz, CD_2Cl_2) δ 164.7 (d, $J_{C-P} = 10.0$ Hz), 162.7 (d, $J_{C-P} = 4.1$ Hz), 161.5 (g, ${}^1J_{C-P} = 50.2$ Hz), 160.4 (d, $J_{C-P} = 50.2$ Hz), 160.4 (d, J_{C-P} = 50.2 Hz), 5.5 Hz), 147.8, 140.6 (d, $J_{C-P} = 0.9$ Hz), 135.3 (d, $J_{C-P} = 1.4$ Hz), 134.0 (br), 128.2 (qq, ${}^{2}J_{C-F} = 31.4$ Hz, ${}^{4}J_{C-F} = 2.8$ Hz), 127.0, 126.4 (d, $J_{C-P} = 7.4$ Hz), 125.7, 124.9 (q, ${}^{1}J_{C-F} = 272.3$ Hz), 116.7 (sept, ${}^{3}J_{C-F} = 4.0$ Hz), 105.2 (d, $J_{C-P} = 4.0$ Hz), 104.4 (d, $J_{C-P} = 5.2$ Hz), 94.6 (d, $J_{C-P} = 9.7$ Hz), 93.4 (d, $J_{C-P} = 13.7$ Hz), 84.8 (d, $J_{C-P} = 24.2 \text{ Hz}$), 63.9 (d, $J_{C-P} = 19.8 \text{ Hz}$), 55.1, 34.7 (d, $J_{C-P} = 4.5 \text{ Hz}$), 34.5 (d, $J_{C-P} = 22.1 \text{ Hz}$), 29.9 (d, $J_{C-P} = 1.9$ Hz), 29.8 (d, $J_{C-P} = 1.9$ Hz), 25.5 (d, $J_{C-P} = 2.4$ Hz), 25.4 (d, $J_{C-P} = 4.5$ Hz); ³¹P NMR $(200 \text{ MHz}, \text{CD}_2\text{Cl}_2) \delta 47.33 \text{ (s)}; \text{HRMS} \text{ (ESI) } m/z 602.1853 \text{ (M}^+), \text{ calc. for } [\text{IrC}_{25}\text{H}_{32}\text{NO}_2\text{P}]^+ 602.1795;$ 863.0658 (BArF), calc. for $[C_{32}H_{12}BF_{24}]^{-}$ 863.0654.

{2-((2*R*,3*R*)-3-(*tert*-butyl)-4-phenyl-2,3-dihydrobenzo[*d*][1,3]oxaphosphol-2-yl)pyridine}(η^4 -1,5cyclooctadiene)iridium (I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (6b). 375 mg red-orange solid, 75% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.11 (d, *J* = 6.0 Hz, 1H), 7.88-7.92 (m, 2H), 7.63 (s, BArF), 7.39-7.47 (m, 5H), 7.43 (s, BArF), 7.36 (t, *J* = 7.8 Hz, 1H), 7.29 (dt, *J* = 6.5, 2.0 Hz, 1H), 6.95 (d, *J* = 8.3 Hz, 1H), 6.88 (dd, *J* = 7.5, 4.0 Hz, 1H), 5.86 (s, 1H), 4.90 (m, 1H), 4.75 (m, 1H), 4.26 (m, 1H), 3.69 (m, 1H), 2.36-2.43 (m, 1H), 2.25-2.31 (m, 2H), 2.05-2.16 (m, 2H), 1.85-2.91(m, 2H), 1.77-1.81 (m, 1H), 0.91 (d, *J*_{H-P} = 15.9 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 163.9 (d, *J*_{C-P} = 9.7 Hz), 161.5 (d, *J*_{C-P} = 4.7 Hz), 161.2 (q, ¹*J*_{C-B} = 50.2 Hz), 147.1, 145.4 (d, *J*_{C-P} = 9.5 Hz), 140.1, 139.8 (d, *J*_{C-P} = 1.8 Hz), 133.7 (br), 133.4 (d, $J_{C-P} = 1.8 \text{ Hz}$), 128.2, 128.0 (qq, ${}^{2}J_{C-F} = 31.6 \text{ Hz}$, ${}^{4}J_{C-F} = 3.0 \text{ Hz}$), 127.8, 127.6, 125.7 (d, $J_{C-P} = 9.6 \text{ Hz}$), 125.5, 125.3 (d, $J_{C-P} = 7.0 \text{ Hz}$), 124.6 (q, ${}^{1}J_{C-F} = 272.8 \text{ Hz}$), 116.4 (sept, ${}^{3}J_{C-F} = 4.0 \text{ Hz}$), 113.1 (d, $J_{C-P} = 38.2 \text{ Hz}$), 111.5 (d, $J_{C-P} = 3.8 \text{ Hz}$), 93.0 (d, $J_{C-P} = 14.3 \text{ Hz}$), 92.6 (d, $J_{C-P} = 9.1 \text{ Hz}$), 83.0 (d, $J_{C-P} = 24.5 \text{ Hz}$), 67.1, 63.1, 34.1 (d, $J_{C-P} = 19.9 \text{ Hz}$), 33.4 (d, $J_{C-P} = 4.6 \text{ Hz}$), 30.4 (d, $J_{C-P} = 2.2 \text{ Hz}$), 28.8 (d, $J_{C-P} = 1.7 \text{ Hz}$), 26.3 (d, $J_{C-P} = 2.7 \text{ Hz}$), 25.5 (d, $J_{C-P} = 4.1 \text{ Hz}$); ³¹P NMR (200 MHz, CDCl₃) δ 47.12 (s); HRMS (ESI) *m*/*z* 648.2047 (M⁺), calc. for [IrC₃₀H₃₄NOP]⁺ 648.2002; 863.0632 (BArF⁻), calc. for [C₃₂H₁₂BF₂₄]⁻ 863.0654.

{2-((2*R*,3*R*)-3-(*tert*-butyl)-4-(2,6-dimethoxyphenyl)-2,3-dihydrobenzo[*d*][1,3]oxaphosphol-2yl)pyridine}(η^4 -1,5-cyclooctadiene)iridium (I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (6c). 418 mg red-orange solid, 86% yield. ¹H NMR (500 MHz, CD₂Cl₂) δ 8.19 (d, *J* = 6.0 Hz, 1H), 7.98-8.03 (m, 2H), 7.64 (s, BArF), 7.47 (s, BArF), 7.41 (dt, *J* = 6.9, 1.8 Hz, 1H), 7.31-7.35 (m, 2H), 6.95 (d, *J* = 8.0 Hz, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 7.72 (dd, *J* = 7.6, 3.9 Hz, 1H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.93 (s, 1H), 4.77-4.83 (m, 1H), 4.37-4.40 (m, 1H), 4.19-4.20 (m, 1H), 3.60-3.65 (m, 1H), 3.62 (s, 3H), 3.55 (s, 3H), 2.38-2.45 (m, 2H), 1.89-2.22 (m, 4H), 1.48-1.56 (m, 2H), 1.06 (d, *J*_{H-P} = 15.8 Hz, 9H); ¹³C NMR (125 MHz, CD₂Cl₂) δ 165.4 (d, *J*_{C-P} = 9.5 Hz), 162.8 (d, *J*_{C-P} = 4.5 Hz), 162.3 (q, ¹*J*_{C-B} = 50.4 Hz), 157.8 (d, *J*_{C-P} = 25.7 Hz), 148.4, 141.4, 139.8 (d, *J*_{C-P} = 10.3 Hz), 135.1 (br), 134.2 (d, *J*_{C-P} = 1.8 Hz), 130.7, 129.4 (qq, ²*J*_{C-F} = 31.6 Hz, ⁴*J*_{C-F} = 2.9 Hz), 127.2 (d, *J*_{C-P} = 1.7 Hz), 127.1, 126.8, 126.0 (q, ¹*J*_{C-F} = 272.7 Hz), 118.2, 117.8 (sept, ³*J*_{C-F} = 4.2 Hz), 112.1 (d, *J*_{C-P} = 3.9 Hz), 104.6 (d, *J*_{C-P} = 17.4 Hz), 93.4 (d, *J*_{C-P} = 7.7 Hz), 89.6 (d, *J*_{C-P} = 16.8 Hz), 84.5 (d, *J*_{C-P} = 4.1 Hz), 25.6 (d, *J*_{C-P} = 2.9 Hz); ³¹P NMR (200 MHz, CD₂Cl₂) δ 50.30 (s); HRMS (ESI) *m/z* 708.2173 (M⁺), calc. for [IrC₃₂H₃₈NO₃P]⁺ 708.2213; 863.0680 (BArF⁻), calc. for [C₃₂H₁₂BF₂₄]⁻ 863.0654.

{2-((2R,3R)-4-(anthracen-9-yl)-3-(*tert*-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphol-2-

yl)pyridine}(η^4 -1,5-cyclooctadiene)iridium (I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (6d). 427 mg red-orange solid, 82% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 8.16 (d, *J* = 8.3 Hz, 1H), 8.12 (d, *J* = 5.2 Hz, 1H), 8.03 (d, *J* = 8.2 Hz, 1H), 7.89-7.95 (m, 2H), 7.63 (s, BArF), 7.59 (d, *J* = 8.7 Hz,

2H), 7.37-7.51 (m, 4H), 7.44 (s, BArF), 7.13 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 7.2 Hz, 1H), 6.88 (d, J = 6.3 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H), 5.94 (s, 1H), 4.46-4.52 (m, 1H), 3.99-4.05 (m, 1H), 3.68-3.75 (m, 1H), 2.35-2.41 (m, 1H), 1.89-1.95 (m, 1H), 1.68-1.81 (m, 3H), 1.49-1.56 (m, 1H), 1.07-1.17 (m, 2H), 0.88 (d, J = 15.9 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 163.5 (d, $J_{C+P} = 9.5$ Hz), 161.5 (d, $J_{C-P} = 4.5$ Hz), 160.1 (q, ¹ $J_{C-B} = 49.8$ Hz), 147.2, 141.7 (d, $J_{C-P} = 10.2$ Hz), 140.1, 133.7 (br), 132.1, 130.6 (d, $J_{C-P} = 32.2$ Hz), 129.3, 128.9, 128.8, 128.0, 127.9 (qq, ² $J_{C-F} = 31.4$ Hz, ⁴ $J_{C-F} = 3.0$ Hz), 127.5, 127.2 (d, $J_{C-P} = 7.1$ Hz), 126.7, 125.9, 125.7 (d, $J_{C-P} = 6.6$ Hz), 125.6, 125.2 (d, $J_{C-P} = 5.1$ Hz), 124.9 (d, $J_{C-P} = 11.6$ Hz), 124.6 (q, ¹ $J_{C-F} = 273.0$ Hz), 124.2, 117.6 (d, $J_{C-P} = 37.5$ Hz), 116.5 (sept, ³ $J_{C-F} = 4.0$ Hz), 112.0 (d, $J_{C-P} = 3.7$ Hz), 92.1 (d, $J_{C-P} = 7.6$ Hz, COD, CH), 89.6 (d, $J_{C-P} = 16.2$ Hz, COD, CH), 83.6 (d, $J_{C-P} = 24.9$ Hz), 65.2 (COD, CH), 62.1 (COD, CH), 33.4 (d, $J_{C-P} = 5.2$ Hz, COD, CH₂), 33.2 (d, $J_{C-P} = 20.2$ Hz), 31.0 (COD, CH₂), 28.2 (COD, CH₂), 25.5 (d, $J_{C-P} = 4.1$ Hz), 23.6 (d, $J_{C-P} = 3.0$ Hz, COD, CH₂); ³¹P NMR (200 MHz, CDCl₃) δ 47.67 (s); HRMS (ESI) *m/z* 748.2315 (M⁺), calc. for [IrC₃₁H₃₆NO₂P]⁺ 748.2313; 863.0654 (BArF⁻), calc. for [C₃₂H₁₂BF₂₄]⁻ 863.0654.

Complex 6e. After addition of NaBArF, the mixture was stirred at rt for 12 h until ³¹P NMR indicated complete conversion. 431 mg light yellow solid was isolated in 87% yield after the same work up as above. ¹H NMR (500 MHz, CDCl₃) δ 7.69 (s, BArF), 7.64 (t, *J* = 8.1 Hz, 1H), 7.49 (s, BArF), 7.45 (t, *J* = 8.5 Hz, 1H), 7.32 (dd, ³*J*_{H-P} = 7.1 Hz, *J* = 5.1 Hz, 1H, OCH₂), 7.23 (d, *J* = 7.1 Hz, 1H), 6.89 (dd, *J* = 8.7, 1.0 Hz, 1H), 6.72 (m, 1H, OCH₂), 6.69 (t, *J* = 4.0 Hz, 1H), 6.66 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.50 (d, *J* = 6.3 Hz, 1H), 4.37-4.39 (m, 1H), 4.29-4.31 (m, 2H), 3.96 (s, 3H), 3.87-3.90 (m, 1H), 2.57-2.62 (m, 2H), 2.18-2.32 (m, 2H), 1.95-2.01 (m, 1H), 1.71-1.75 (m, 1H), 1.51-1.53 (m, 1H), 1.21 (d, *J* = 17.0 Hz, 9H), 0.83-0.93 (m, 1H), -13.34 (dd, ²*J*_{H-P} = 22.8 Hz, *J* = 3.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 167.9 (d, *J*_{C-P} = 9.3 Hz), 162.5 (d, *J* = 6.3 Hz), 162.3 (q, ¹*J*_{C-B} = 50.2 Hz), 160.3 (d, *J*_{C-P} = 3.8 Hz), 153.1 (d, *J*_{C-P} = 7.8 Hz), 141.6 (d, *J*_{C-P} = 1.4 Hz), 136.5 (d, *J*_{C-P} = 1.7 Hz), 134.8 (br), 129.0 (qq, ²*J*_{C-F} = 31.5 Hz, ⁴*J*_{C-F} = 2.8 Hz), 125.6 (q, ¹*J*_{C-F} = 272.7 Hz), 117.7 (d, *J*_{C-P} = 9.5 Hz), 117.4 (sept, ³*J*_{C-F} = 4.1Hz), 111.1, 106.7 (d, *J*_{C-P} = 3.8 Hz), 105.6 (d, *J*_{C-P} = 5.4 Hz), 104.3 (d, *J*_{C-P} = 38.2 Hz), 101.2 (t, *J*_{C-P} = 2.3 Hz), 95.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 63.0 (d, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9 Hz, COD, CH), 65.3 (d, *J*_{C-P} = 3.6 Hz), 101.2 (t, *J*_{C-P} = 1.9

COD, CH), 61.6 (dd, J = 57.0, 0.8 Hz, CH₂O), 55.7, 34.2 (dd, $J_{C-P} = 24.8$, 0.8 Hz), 32.8 (d, $J_{C-P} = 4.5$ Hz, COD, CH₂), 31.7 (COD, CH₂), 26.3 (d, J = 3.6 Hz, COD, CH₂), 25.8 (COD, CH₂), 25.4 (d, $J_{C-P} = 3.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 46.45 (d, J = 6.5 Hz); HRMS (ESI) *m/z* 632.1863 (M⁺), calc. for [IrC₂₆H₃₄NO₃P]⁺ 632.1900; 863.0648 (BArF⁻), calc. for [C₃₂H₁₂BF₂₄]⁻ 863.0654.

Complex 6f. The mixture was stirred at rt for 30 min after addition of NaBArF. Complete conversion was observed by ³¹P NMR. 404 mg light yellow solid was isolated in 79% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.22 (dd, J = 7.9, 5.4 Hz, 1H), 7.96 (dd, J = 8.4, 1.3 Hz, 1H), 7.87 (t, J = 7.8 Hz, 1H), 7.79 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (t, J = 7.8, 1.3 Hz, 1H), 7.96 (dd, J = 7.8, 1.3 Hz, 1H), 7.87 (t, J = 7.8, 1.3 Hz, 1H), 7.96 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.96 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.96 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.96 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.96 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.87 (td, J = 7.8, 1.3 Hz, 1H), 7.96 (td, 1.7 Hz, 1H), 7.69 (br s, BArF), 7.62 (dd, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.52 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (br s, BArF), 7.36 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (m, 2H), 7.49 (t, J = 7.4, 1.4 Hz, 1H), 7.59 (t, J = 7.4, 1H), 7.59 (t, J = 7.4, 1H), 7.59 (t, J = 7.4, 1H), 7.59 (t, J =7.8 Hz, 1H), 6.69-6.74 (m, 2H), 6.59 (d, J = 6.3 Hz, 1H), 4.85-4.91 (m, 1H), 4.45-4.49 (m, 2H), 3.99 (s, 3H), 3.19 (br t, J = 8.1 Hz, 1H), 2.74-2.80 (m, 1H), 2.33-2.43 (m, 2H), 1.88-2.06 (m, 2H), 1.61-1.63 (m, 1H), 1.20 (d, J = 17.6 Hz, 9H), 0.82-1.04 (m, 2H), -13.09 (d, ${}^{2}J_{H-P} = 19.4$ Hz, 1H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 166.4 (d, $J_{C-P} = 6.3$ Hz), 162.6 (d, $J_{C-P} = 6.8$ Hz), 161.5 (q, ${}^{1}J_{C-B} = 50.0$ Hz), 160.2 (d, $J_{C-P} = 3.6$ Hz), 156.3 (d, $J_{C-P} = 9.3$ Hz), 149.6, 148.9, 145.2, 139.7, 137.6, 136.8 (d, $J_{C-P} = 1.4$ Hz), 134.7 (br), 131.9 (d, $J_{C-P} = 5.0 \text{ Hz}$), 129.3 (qq, ${}^{2}J_{C-F} = 31.2 \text{ Hz}$, ${}^{4}J_{C-F} = 3.0 \text{ Hz}$), 127.3 (d, $J_{C-P} = 2.8 \text{ Hz}$), 125.8 (q, ${}^{1}J_{C-F} = 3.0 \text{ Hz}$) 272.6 Hz), 124.7, 122.7 (d, $J_{C-P} = 9.3$ Hz), 121.4, 117.4 (sept, ${}^{3}J_{C-F} = 3.9$ Hz), 106.9 (d, $J_{C-P} = 3.7$ Hz), 105.9 (d, $J_{C-P} = 5.2$ Hz), 105.4, 104.8 (d, $J_{C-P} = 38.7$ Hz), 93.1 (d, $J_{C-P} = 29.4$ Hz, COD, CH), 92.1 (COD, CH), 73.8 (d, $J_{C-P} = 1.5$ Hz, COD, CH), 72.0 (d, $J_{C-P} = 4.0$ Hz, COD, CH), 55.8, 34.6 (d, $J_{C-P} = 24.6$ Hz), 34.3 (d, $J_{C-P} = 5.2$ Hz, COD, CH₂), 29.1 (COD, CH), 29.0 (COD, CH), 25.3 (COD, CH), 25.2 (d, $J_{C-P} =$ 3.6 Hz); ³¹P NMR (160 MHz, CDCl₃) δ 49.72 (d, J = 4.0 Hz); HRMS (ESI) m/z 678.2071 (M⁺), calc. for $[IrC_{31}H_{36}NO_2P]^+$ 678.2107; 863.0671 (BArF⁻), calc. for $[C_{32}H_{12}BF_{24}]^-$ 863.0654.

General procedure for asymmetric hydrogenation of alkenes. A high pressure steel autoclave (HEL CAT 24) with a glass insert equipped with a magnetic stir bar was taken into a glove box. The glass insert was loaded with alkene 7a (20 mg, 0.138 mmol), freshly prepared catalyst 6a (4.0 mg, 0.0028 mmol) and 0.5 mL CH₂Cl₂. The vessel was sealed and taken out of the box. The reactor was purged with N₂ and then H₂, and stirred under 400 psi H₂ and rt for 18 h. The reactor was then vented. The reaction conversion and enantiomeric ratio were determined by chiral analysis.²²

ACKNOWLEDGEMENTS

The authors thank Mr. Keith McKellop and Mr. Scott Pennino for HRMS analyses. We thank one of the reviewers for the helpful comments on the complex structures.

Supporting Information

Copies of ¹H and ¹³C NMR spectra of the compounds, crystallographic data of **4a** and chiral HPLC

analyses of 4e and 5e. This material is available free of charge via the Internet at http://pubs.acs.org.

REFERENCES

- (1) For reviews, see: (a) Palmer, A. M.; Zanotti-Gerosa, A. *Curr. Opin. Drug Discov. Devel.* 2010, *13*, 698. (b) Shang, G.; Li, W.; Zhang, X. In Catalytic Asymmetric Synthesis 3rd Edition; Ojima, I., Ed.; Wiley: Hoboken, 2010; pp 343-436. (c) Lennon, I. C.; Moran, P. H. *Curr. Opin. Drug Discov. Devel.* 2003, *61*, 855. (d) Blaser, H.-U.; Malan, C.; Pugin, B.; Spindler, F.; Steiner, H.; Studer, M. *Adv. Synth. Catal.* 2003, *345*, 103. (e) Busacca, C. A.; Senanayake, C. H. In *Comprehensive Chirality*; Carreira, E.; Yamamoto H., Ed.; Elsevier: Frankfurt, 2012; pp 167-216.
- (2) (a) Han, Z. S.; Goyal, N.; Herbage, M. A.; Sieber, J. D.; Qu, B.; Xu, Y.; Li, Z.; Reeves, J. T.; Desrosiers, J.-N.;
 Ma, S., Grinberg, N.; Lee, H.; Mangunuru, H. P. R.; Zhang, Y.; Krishnamurthy, D.; Lu, B. Z.; Song, J. J.; Wang,
 G.; Senanayake, C. H. *J. Am. Chem. Soc.* 2013, *135*, 2474. (b) Imamoto, T.; Tamura, K.; Zhang, Z.; Horiuchi, Y.;
 Sugiya, M.; Yoshida, K.; Yanagisawa, A.; Gridnev, I. D. *J. Am. Chem. Soc.* 2012, *134*, 1754. (c) Tang, W.;
 Zhang, X. *Chem. Rev.* 2003, *103*, 3029. (d) Genet, J.-P. *Acc. Chem. Res.* 2003, *36*, 908.
- (3) (a) Kagan, H. B.; Phat, D.-T. J. Am. Chem. Soc. 1972, 94, 6429. (b) Kagan, H. B.; Langloi, N.; Phat, D.-T. J. Am. Chem. Soc. 1975, 90, 353. (c) Knowles, W. S. Angew. Chem. Int. Ed. 2002, 41, 1998. (d) Knowles, W. S.; Noyori, R. Acc. Chem. Res. 2007, 40, 1238. (e) Noyori, R. Angew. Chem. Int. Ed. 2002, 41, 2008. (f) Bell, S.; Wüstenberg, B.; Kaiser, S.; Menges, F.; Netscher, T.; Pfaltz, A. Science 2006, 311, 642.
- (4) (a) Margalef, J.; Lega, M.; Ruffo, F.; Pàmies, O.; Diéguez, M. *Tetrahedron: Asymm* 2012, 23, 945. (b) Woodmansee, D. H.; Pfaltz, A. *Top. Organomet. Chem.* 2011, 34, 31. (c) Bunlaksananusorn, T.; Polborn, K.; Knochel, P. *Angew. Chem. Int. Ed.* 2003, 42, 3941. (d) Drury, W. J. (III); Zimmermann, N.; Keenan, M.; Hayashi, M.; Kaiser, S.; Goddard, R.; Pfaltz, A. *Angew. Chem. Int. Ed.* 2004, 43, 70. (e) Liu, Q.-B.; Yu, C.-B.; Zhou, Y.-G. *Tetrahedron Lett.* 2006, 47, 4733.

- (5) (a) Tang, W.; Qu, B.; Capacci, A. G.; Rodriguez, S.; Wei, X.; Haddad, N.; Narayanan, B.; Ma, S.; Grinberg, N. Yee, N. K.; Krishnamurthy, D.; Senanayake, C. H. Org. Lett. 2010, 12, 176. (b) Tang, W.; Capacci, A. G.; White, A.; Ma, S.; Rodriguez, S.; Qu, B.; Savoie, J.; Patel, N. D.; Wei, X.; Haddad, N.; Grinberg, N.; Yee, N. K.; Krishnamurthy, D.; Senanayake, C. H. Org. Lett. 2010, 12, 1104.
 - (6) (a) Tang, W.; Capacci, A. G.; Wei, X.; Li, W.; White, A.; Patel, N. D.; Savoie, J.; Gao, J. J.; Rodriguez, S.; Qu, B.; Haddad, N.; Lu, B. Z.; Krishnamurthy, D.; Yee, N. K.; Senanayake, C. H. *Angew. Chem. Int. Ed.* 2010, 49, 5879. (b) Rodriguez, S.; Qu, B.; Haddad, N.; Reeves, D.; Tang, W.; Krishnamurthy, D.; Senanayake, C. H. *Adv. Catal. Syn.* 2011, 353. 533.
- (7) For a review, see: (a) Brown, J. M. In *Comprehensive Asymmetric Catalysis*; Jacobsen, E. N.; Pfaltz, A.;
 Yamamoto, H., Ed.; Springer-Verlag, Berlin, 1999; pp 121-182. (b) Xie, J.-H.; Zhu, S.-F.; Zhou, Q.-L. *Chem. Rev.* 2011, *111*, 1713. (c) Schmidt, T.; Dai, Z.; Drexler, H.-J.; Baumann, W.; Jaeger, C.; Pfeifer, D.; Heller, D. *Chem. Eur. J.* 2008, *14*, 4469. (d) Mori, S.; Vreven, T.; Morokuma. K. *Chem. Asian J.* 2006, *1*, 391. (e) Kagan,
 H. B.; Langlois, N.; Dang. T. P. *J. Organomet. Chem.* 1975, *90*, 353. (f) Halpern, J.; Riley, D. P.; Chan, A. S. C.;
 Pluth, J. J. *J. Am. Chem. Soc.* 1977, *99*, 8055. (g) Brown, J. M.; Chaloner, P. A. *J. Chem. Soc. Chem. Comm.*1980, 344. (h) Landis, C. R.; Halpern, J. *J. Am. Chem. Soc.* 1987, *109*, 1746. (i) Sun Y. K.; Landau R. N.; Wang,
 J.; LeBlond, C.; Blackmond, D. G. *J. Am. Chem. Soc.* 1996, *118*, 1348.
- (8) (a) Wills, M. Science 2006, 311, 619. (b) Cui, X.; Burgess, K. Chem. Rev. 2005, 105, 3272.
- (9) (a) Smidt, S. P.; Zimmermann, N.; Studer, M.; Pfaltz, A. *Chem. Eur. J.* 2004, *10*, 4685. (b) Roseblade, S. J.;
 Pfaltz, A. *Acc. Chem. Res.* 2007, *40*, 1402. (c) Woodmansee, D. H.; Pfaltz, A. *Chem. Comm.* 2011, *47*, 7912. (d)
 Helmchen, G.; Pfaltz, A. *Acc. Chem. Res.* 2000, *33*, 336. (e) Menges, F.; Neuburger, M.; Pfaltz, A. *Org. Lett.*2002, *4*, 4713. (f) Blankenstein, J.; Pfaltz, A. *Angew. Chem. Int. Ed.* 2001, *40*, 4445. (g) Menges, F.; Pfaltz, A. *Adv. Synth. Catal.* 2002, *344*, 40. (h) Powell, M. T.; Hou, D.-R.; Perry, M. C.; Cui, X.; Burgess, K. J. Am. Chem. *Soc.* 2001, *343*, 450. (i) Hou, D.-R.; Reibenspies, J.; Colacot, T. J.; Burgess, K. *Chem. Eur. J.* 2001, *7*, 5391. (j)
 Kaiser, S.; Smidt, S. P.; Pfaltz, A. *Angew. Chem. Int. Ed.* 2006, *45*, 5194.
- (10) Busacca, C. A.; Wei. X.; Haddad, N.; Kapadia, S.; Lorenz, J. C.; Saha, A. K.; Varsolona, R. J.; Berkenbusch, T.; Campbell, S. C.; Farina, V.; Feng, X.; Gonnella, N. C.; Grinberg, N.; Jones, P.-J.; Lee, H.; Li, Z.; Niemeier, O.; Samstag, W.; Sarvestani, M.; Schroeder, J.; Smoliga, J.; Spinelli, E. M.; Vitous, J.; Senanayake, C. H. *Asian J. Org. Chem.* 2012, *1*, 80.

- (11) Trankle, W. G.; Kopach, M. E. Org. Proc. Res. Dev. 2007, 11, 913.
- (12) (a) Zhu, W.; Ma, D. J. Org. Chem. 2005, 70, 2696. (b) Cacchi, S.; Fabrizi, G.; Goggiamani, A.; Parisi, L. M.;
 Bernini, R. J. Org. Chem. 2004, 69, 5608.
- (13) Maloney, K. M.; Kuethe, J. T.; Linn, K. Org. Lett. 2011, 13, 102.
- (14) Crystallographic data for compound 4a was deposited in the Cambridge Crystallographic Data Centre CCDC955445. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif.
- (15) Lightfoot, A.; Schnider, P.; Pfaltz, A. Angew. Chem. Int. Ed. 1998, 37, 2897.
- (16) Schrems, M. G.; Neumann, E.; Pfaltz, A. Agnew. Chem. Int. Ed. 2007, 46, 8274.
- (17) Busacca, C. A.; Qu, B.; Grět, N.; Fandrick, K. R.; Saha, A. K.; Marsini, M.; Reeves, D.; Haddad, N.; Eriksson, M.; Wu, J.-P.; Grinberg, N.; Lee, H.; Li, Z.; Lu, B. Z.; Chen, D.; Hong, Y.; Ma, S.; Senanayake, C. H. *Adv. Synth. Catal.* 2013, *355*, 1455.
- (18) Tang, W.; Keshipeddy, S.; Zhang, Y.; Wei, X.; Savoie, J.; Patel, N. D.; Yee, N. K.; Senanayake, C. H. Org. Lett. **2011**, 13, 1366.
- (19) Bonnet, V.; Mongin, F.; Trecourt, F.; Queguiner, G.; Knochel, P. Tetrahedron 2002, 58, 4429.
- (20) The chiral analysis of the phosphine oxide 4e was determined by HPLC Chiralpak AD-3, 4.6 × 150 mm, 2.72 min and 3.49 min. The chiral analysis of the corresponding free ligand 5e was determined by HPLC Chiralpak AD-H, 4.6 × 250 mm, 3.75 min and 4.13 min. See the Supporting Information for details.
- (21) See examples of C-H activation in iridium complexes: (a) Wheatley, J. E.; Ohlin, C. A.; Chaplin, A. B. *Chem. Commun.* 2014, *50*, 685. (b) Kiener, C. A.; Shu, C.; Incarvito, C.; Hartwig J. F. J. Am. Chem. Soc. 2003, *125*, 14272. (c) Werner, H.; Schulz, M.; Windmüller, B. *Organometallics* 1995, *14*, 3659.
- (22) 8a: chiral GC analysis using Chiraldex B-PH 30 m × 0.25 mm × 0.12 μm column at 90 °C and 1.0 mL/min, 13.61 min and 13.89 min; 8b: chiral HPLC analysis using Chiralcel OJ-3 column 4.6 × 150 mm, heptane/ethanol = 99:1, 0.9 ml/min, 4.25 min and 6.55 min; 8c: chiral GC analysis using Chiraldex B-PH column at 150 °C and 1.0 mL/min, 10.39 min and 10.99 min; 8d: chiral GC analysis using Chiraldex B-PH column at 120 °C and 1.0 mL/min, 10.22 min and 10.55 min; 8e: chiral HPLC analysis using Chiralcel OJ-H, heptane/*i*PrOH = 95/5, 1.0 mL/min, IPA as diluent, 4.52 min and 4.84 min.